Roche Holding AG
SIX:ROG
Roche Holding AG
SIX:ROG
Price:
220 CHF
-0.05%
Market Closed
Updated:
Apr 19, 2024
Roche Holding AG
Capital Expenditures
Last
Value
3-Years CAGR
5-Years CAGR
|
Roche Holding AG
Capital Expenditures Peer Comparison
Comparables:
NOVN
CYTO
NLSP
S
SDZ
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Roche Holding AG
SIX:ROG
|
Capital Expenditures
CHf-10.9B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-14%
|
|
|
Novartis AG
SIX:NOVN
|
Capital Expenditures
$-2.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
2%
|
|
|
Altamira Therapeutics Ltd
NASDAQ:CYTO
|
Capital Expenditures
CHf-2.1m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-70%
|
CAGR 10-Years
N/A
|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Capital Expenditures
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Capital Expenditures
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Roche Holding AG's Capital Expenditures?
Capital Expenditures
-10.9B
CHF
-10.9B
CHF
Based on the financial report for Dec 31, 2023, Roche Holding AG's Capital Expenditures amounts to -10.9B CHF.
What is Roche Holding AG's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-14%
-14%
Over the last year, the Capital Expenditures growth was -127%. The average annual Capital Expenditures growth rates for Roche Holding AG have been -11% over the past three years , -10% over the past five years , and -14% over the past ten years .
You don't have any saved screeners yet
